A substance being studied in the treatment of follicular non-Hodgkin lymphoma. It binds to the protein CD80, which is found on certain normal white blood cells and on white blood cells that are cancer. It is a type of monoclonal antibody.
A humanized IgG1 monoclonal antibody directed against CD80, the natural ligand for the T-cell antigen CD28 which mediates T-cell and B-cell adhesion. Galiximab binds to CD80 expressed on the cell surfaces of follicular lymphomas, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC). CD80 is expressed on activated B-cells and gamma-interferon-stimulated monocytes and is often expressed at low levels on the surfaces of follicular lymphoma cells and other lymphoid malignancies.
A monoclonal antibody that is being studied in the treatment of follicular non-Hodgkin's lymphoma. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Galiximab binds to the protein CD80, which is found on certain normal and cancerous white blood cells.